ISPR

Business Context and Reporting Period

Company: Ispire Technology Inc. (ISPR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2024
Business Overview: Ispire is a holding company engaged in the research, development, and distribution of branded e-cigarettes and cannabis vaping products. Operations are conducted primarily through subsidiaries Aspire North America (cannabis) and Aspire Science (nicotine). The company recently established subsidiaries in the UAE and California to expand sales and logistics.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue remained relatively flat for the three-month period (+0.3% YoY) but declined 4.0% for the six-month period. This was driven by significant growth in Europe (+53% for 3 months) and Africa (+3,000%+ for 3 months), offset by a sharp decline in North America (-45% for 3 months) and Asia Pacific (-40% for 3 months).
• Profitability: Gross margin improved from 15.0% to 18.5% (3 months) and 15.5% to 19.0% (6 months) due to a shift toward higher-margin products. However, operating expenses surged 48.3% (3 months) and 56.6% (6 months), primarily due to increased bad debt provisions and stock-based compensation.
• Bad Debt Expense: A significant non-cash charge of $7.29 million was recorded for credit losses in the six months ended Dec 31, 2024, compared to $2.13 million in the prior year period. The allowance for credit losses increased to $11.31 million.
• Liquidity: Net cash provided by operating activities turned positive at $0.43 million for the six months ended Dec 31, 2024, a stark improvement from a $20.23 million outflow in the prior year period. This was largely due to the increase in related party payables.

Guidance, Outlook, Risks, and Unusual Items

• Cost Reduction Initiative: In February 2025 (subsequent event), the company executed a cost reduction initiative expected to save over $4.0 million annually in salary and benefits.
• Regulatory Risks: The company faces significant regulatory hurdles in the U.S. market regarding FDA Premarket Tobacco Product Applications (PMTAs). While a PMTA was submitted for a disposable product in September 2024, the company has ceased marketing tobacco vaping products in the U.S. due to low sales volume relative to regulatory costs.
• Related Party Concentration: The company is heavily reliant on a single related-party supplier, Shenzhen Yi Jia (95% owned by the Co-CEO), which accounted for 93% of total purchases in the six months ended Dec 31, 2024. Accounts payable to this related party totaled $86.38 million.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2024. Material weaknesses were identified regarding the recording of assets from controlling stockholders, evaluation of significant estimates (inventory and credit loss reserves), and lack of comprehensive accounting policies.
• Joint Venture: The company holds a 40% interest in IKE Tek LLC, a joint venture for age-verification technology. The company recorded a share of the joint venture's net loss of $176,668 for the six-month period.

Investor Verification Checklist

• Related Party Payables: Verify the terms and repayment schedule of the $86.38 million payable to Shenzhen Yi Jia, a related party controlled by the Co-CEO.
• Credit Loss Reserves: Assess the methodology and assumptions used to calculate the $11.31 million allowance for credit losses, given the material weakness in internal controls regarding this estimate.
• U.S. Market Strategy: Confirm the status of the PMTA application and the timeline for potential re-entry into the U.S. nicotine market.
• Cost Savings Realization: Monitor the execution of the February 2025 cost reduction initiative to ensure the projected $4.0 million in annual savings is realized.
• Internal Control Remediation: Review the company's plan to remediate the identified material weaknesses in internal controls over financial reporting.